Preprint
Review
Antibodies to SARS-CoV-2 and Their Potential for Therapeutic Passive Immunization
Altmetrics
Downloads
1150
Views
726
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Preprints on COVID-19 and SARS-CoV-2
Submitted:
17 April 2020
Posted:
19 April 2020
You are already at the latest version
Alerts
Abstract
We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID- 19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients and with monoclonal antibodies against the viral S-protein. The development of vaccines against SARS-CoV-2, an essential public health tool, will also be informed by an understanding of the antibody response in infected patients. Although virus-neutralizing antibodies are likely to protect, antibodies could potentially trigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection. An awareness of these possibilities may benefit clinicians and the developers of antibody-based therapies and vaccines.
Keywords:
Subject: Biology and Life Sciences - Virology
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
MDPI Initiatives
Important Links
© 2024 MDPI (Basel, Switzerland) unless otherwise stated